ICON PLC

ICLR

174.880USD

-1.480-0.84%

Close 09/05, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

51 / 686

Overall Ranking

135 / 4731

Industry

Pharmaceuticals & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 19 analysts

Buy

Current Rating

220.533

Target Price

+26.11%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 56.63.

Overvalued

The company’s latest PE is 17.90, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 74.28M shares, decreasing 13.23% quarter-over-quarter.

Held by Ruane Cunniff

Star Investor Ruane Cunniff holds 1.71M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.06.

The company's current financial score is 7.34, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 2.00B, representing a year-over-year decrease of 4.26%, while its net profit experienced a year-over-year decrease of 17.76%.

Score

Industry at a Glance

Previous score

7.34

Change

0



Financials

6.86

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.75

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.54

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.39

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.15

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.80, which is higher than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is 17.81, which is -8.28% below the recent high of 16.34 and 15.13% above the recent low of 15.12.

Score

Industry at a Glance

Previous score

1.80

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 51/686

No Data

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for ICON PLC is 220.00, with a high of 240.00 and a low of 180.00.

Score

Industry at a Glance

Previous score

7.89

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 8.92, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 185.50 and the support level at 158.60, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.87

Change

-0.1

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-05

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 95.51%, representing a quarter-over-quarter decrease of 6.33%. The largest institutional shareholder is Ruane Cunniff, holding a total of 1.71M shares, representing 2.20% of shares outstanding, with 40.16% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

897.65K

+21.71%

4.29M

+2097.19%

1.01M

+3.76%

Star Investors

1.25M

-0.88%

1.66M

+48.87%

Star Investors

815.58K

-38.11%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.18, which is lower than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 1.20. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

ICON PLC

ICLR

6.75 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.64 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

7.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

7.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.